JP2009519974A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519974A5
JP2009519974A5 JP2008545979A JP2008545979A JP2009519974A5 JP 2009519974 A5 JP2009519974 A5 JP 2009519974A5 JP 2008545979 A JP2008545979 A JP 2008545979A JP 2008545979 A JP2008545979 A JP 2008545979A JP 2009519974 A5 JP2009519974 A5 JP 2009519974A5
Authority
JP
Japan
Prior art keywords
compound
medicament
effective amount
aurora kinase
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008545979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/062112 external-priority patent/WO2007120333A2/en
Publication of JP2009519974A publication Critical patent/JP2009519974A/ja
Publication of JP2009519974A5 publication Critical patent/JP2009519974A5/ja
Pending legal-status Critical Current

Links

JP2008545979A 2005-12-16 2006-12-14 四環系キナーゼ阻害剤 Pending JP2009519974A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75123405P 2005-12-16 2005-12-16
PCT/US2006/062112 WO2007120333A2 (en) 2005-12-16 2006-12-14 Tetracyclic kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2009519974A JP2009519974A (ja) 2009-05-21
JP2009519974A5 true JP2009519974A5 (enExample) 2010-02-04

Family

ID=38610005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545979A Pending JP2009519974A (ja) 2005-12-16 2006-12-14 四環系キナーゼ阻害剤

Country Status (6)

Country Link
US (1) US20090131407A1 (enExample)
EP (1) EP1968581A4 (enExample)
JP (1) JP2009519974A (enExample)
AU (1) AU2006342024A1 (enExample)
CA (1) CA2631871A1 (enExample)
WO (1) WO2007120333A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
EP2240481A1 (en) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
RU2010137300A (ru) 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
AU2009300357B2 (en) * 2008-09-23 2014-07-03 The Johns Hopkins University Fused diimidazodiazepine compounds and methods of use and manufacture thereof
CN102177151A (zh) 2008-10-09 2011-09-07 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
MX2011004954A (es) 2008-11-10 2011-05-30 Hoffmann La Roche Moduladores heterociclicos de gamma-secretasa.
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
CN106674081A (zh) * 2016-12-18 2017-05-17 南京理工大学 一种3‑甲硫基吲哚衍生物合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772325A (en) * 1972-03-24 1973-11-13 American Cyanamid Co Novel hexahydro cyclohept(b)indoles
ID30132A (id) * 1998-11-06 2001-11-08 Basf Ag Turunan-turunan pirazol trisiklik
US20060264493A1 (en) * 2003-02-17 2006-11-23 Ermes Vanotti Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20070254877A1 (en) * 2004-06-02 2007-11-01 Takada Pharmaceutical Company Limited Indole Derivative and Use for Treatment of Cancer

Similar Documents

Publication Publication Date Title
WO2007126841A3 (en) Inhibition of alpha-synuclein toxicity
JP2009536652A5 (enExample)
EP2018377A4 (en) 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR CONDITION IN WHICH THE INHIBITION OF HUMAN NEUTROPHILUS ELASTASE HAS A BENEFIT EFFECT
JP2009519974A5 (enExample)
LTPA2019504I1 (lt) Pagerintos TM nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
JP2009039101A5 (enExample)
JP2009513660A5 (enExample)
JP2009524695A5 (enExample)
WO2011022440A3 (en) Heat shock protein binding compounds, compositions, and methods for making and using same
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
PL2029642T3 (pl) Kompozycja katalizatora do kopolimeryzacji propylenu
BRPI0810646A2 (pt) " compostos farmacêuticos ".
SE0950453L (sv) Säkra finansiella transaktioner
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
IT1391030B1 (it) Veicolo del tipo a guida a cavalcioni avente un cilindro principale posteriore
EP3276004A3 (en) Methods for treating chronic kidney disease
EP2087890A4 (en) PREPARING WITH DELAYED RELEASE FOR TISSUE GENERATION THERAPY
FI20065407A0 (fi) Vaikeasti väärennettävissä oleva hologrammi
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
CL2007003467A1 (es) Metodo para el tratamiento de una enfermedad proliferativa seleccionada a partir de sindrome mielodisplasico o leucemia mieloblastica aguda que comprende administrar a) un inhibidor de desacetilasa de histona (hdac) de formula definida en combinacion
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
JP2007520565A5 (enExample)
EP1970063A4 (en) THERAPEUTIC AGENT AGAINST DIABETES
CL2008000596A1 (es) Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
WO2008028963A3 (en) Calreticulin for its use as a medication for the treatment of cancer in a mammal